ALVO Stock Recent News

REYKJAVIK, ICELAND and LONDON, UK (May 28, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into an agreement to expand their commercial partnership to cover three additional biosimilar candidates.

REYKJAVIK, Iceland and LONDON, May 28, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the companies have entered into an agreement to expand their commercial partnership to cover three additional biosimilar candidates.

The Annual General Meeting of Alvotech will be held on Wednesday June 25, 2025, at 09.00 a.m. CEST at the premises of Arendt & Medernach at 41A, Avenue John F. Kennedy L-1855 Luxembourg, Grand Duchy of Luxembourg.

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 95,000 shares in Alvotech at ISK 1,260 per share, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. The date of the transaction is May 20, 2025. Alvogen Lux Holdings' largest shareholders are CVC (40%), Aztiq (30%) and Temasek (20%).

REYKJAVIK,  ICELAND AND STOCKHOLM, SWEDEN (May 19, 2025) — Alvotech (NASDAQ: ALVO, the “Company”) has entered into agreement with DNB Carnegie Investment Bank AB (publ) (“DNB Carnegie”) regarding liquidity provider services to ensure liquidity in the Company's Swedish Depository Receipts (“SDRs”), equity share equivalents, trading on Nasdaq Stockholm. The arrangement is in accordance with the framework of Nasdaq Stockholm's rules on liquidity providers.

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Not to be released, published, distributed or circulated in any jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities.

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 19,988 shares in Alvotech at USD 10.18 per share, by Richard Davies, Deputy Chairman of the Board of Directors Alvotech. The transaction is dated May 14, 2025.

Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 210,000 shares in Alvotech at ISK 1,277.38, by Alvogen Lux Holdings S.ár.l., the second largest shareholder in Alvotech. Alvogen Lux Holdings' largest shareholders are CVC (40%), Aztiq (30%) and Temasek (20%).

Alvotech (NASDAQ:ALVO ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Benedikt Stefansson - VP, Investor Relations and Global Communications Robert Wessman - Founder, Chairman and CEO Anil Okay - Chief Commercial Officer Joel Morales - Chief Financial Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Operator Good day, and thank you for standing by. Welcome to the Alvotech Q1 2025 Earnings Conference Call.